SAM Post Award Notification - Orexo.pdf
PDF 95 KB Posted
- Attached to
- Notice of Contract Award - Orexo US, Inc.
- Solicitation number
- Not on record
About this file
This document is a federal contract award notice for a clinical research and development contract. The contract (Number 75A50125C00010) was awarded to Orexo US, Inc. on 9/24/2025 for a total value of $67,863,006, covering Contract Line Items (CLINs) 0001-0006. The contract is for clinical development of OX390 (atipamezole), a pharmaceutical research project focused on creating an α2 agonist reversal agent to counteract sedative effects of certain drugs in overdose scenarios, particularly in cases where naloxone provides only partial resuscitation.
The contract was solicited under Solicitation Number BAA-23-100-SOL-00004 by the Department of Health and Human Services (HHS), located at the Constitution Center in Washington, D.C. The project falls under NAICS Code 541714 for Research and Development in Physical, Engineering, and Life Sciences, with a Product Service Code (PSC) of AN13 for Health R&D Services. The place of contract performance is the United States, and the contract has no specific set-aside status. The contracting officer is identified as Jonathan Gonzalez, and the contractor's unique entity identifier (UEI) is MN1MPMBCVVD5.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Contract Number: 75A50125C00010
Awarded: 9/24/2025
Contracting Office ZIP Code: 20024
PSC: AN13 - Health R&D Services; Health care services; Experimental Development NAICS Code: 541714 -Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Contracting Office Address:
Constitution Center, 400 7th St SW Washington, D.C. 20024
Subject: Award Notice: 75A50125C00010
Solicitation Number: BAA-23-100-SOL-00004
Contracting Officer: Jonathan Gonzalez@hhs.gov
Total Contract Award Value (base and all options): $67,863,006
Line Item Number: CLIN 0001 – CLIN 0006
Contract Award Date: 9/24/2025
Contractor: Orexo US, Inc.
UEI: MN1MPMBCVVD5
Contractor Awarded Address: Morristown, New Jersey 07960-3965
Description: Clinical development of OX390 (atipamezole) as an α2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other α2 agonists that are increasingly found in combination with IMF. In cases of overdose, where there is only partial or no resuscitation with naloxone, OX390 would be an empirical treatment in areas where xylazine or other α2-adrenergic agonists have been identified in the illicit drug supply, potentially leading to partial or full resolution of residual CNS depression.
Place of Contract Performance: United States
Set-aside Status: N/A mailto:Gonzalez@hhs.gov
File details come from the government source that posted it. Updated .